PE20200173A1 - Anticuerpos anti-trkb - Google Patents
Anticuerpos anti-trkbInfo
- Publication number
- PE20200173A1 PE20200173A1 PE2019002525A PE2019002525A PE20200173A1 PE 20200173 A1 PE20200173 A1 PE 20200173A1 PE 2019002525 A PE2019002525 A PE 2019002525A PE 2019002525 A PE2019002525 A PE 2019002525A PE 20200173 A1 PE20200173 A1 PE 20200173A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- amino acid
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Referida a un anticuerpo anti-TrkB o un fragmento de fijacion al antigeno de este que comprende: a) una region variable de cadena liviana que comprende la secuencia de aminoacidos SEQ ID NO:48 (L-CDR1), SEQ ID NO:49 (L-CDR2) y SEQ ID NO:50 (L-CDR3); y b) una region variable de cadena pesada que comprende las secuencias de aminoacidos de SEQ ID NO:51 (H-CDR1), SEQ ID NO:52 (H-CDR2) y SEQ ID NO:53 (H-CDR3), o c) una region variable de cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO:55 (H-CDR1), SEQ ID NO:56 (H-CDR2) y SEQ ID NO:57 (H-CDR3) o d) una region variable de cadena pesada que comprende la secuencia de aminoacidos de SEQ ID NO:58 (H-CDR1), SEQ ID NO:59 (H-CDR2) y SEQ ID NO:60 (H-CDR3)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17175122 | 2017-06-09 | ||
| PCT/EP2018/065107 WO2018224630A1 (en) | 2017-06-09 | 2018-06-08 | Anti-trkb antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200173A1 true PE20200173A1 (es) | 2020-01-24 |
Family
ID=59034551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002525A PE20200173A1 (es) | 2017-06-09 | 2018-06-08 | Anticuerpos anti-trkb |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10793634B2 (es) |
| EP (1) | EP3635004A1 (es) |
| JP (2) | JP7267208B2 (es) |
| KR (1) | KR20200017421A (es) |
| CN (1) | CN110719916B (es) |
| AR (1) | AR112602A1 (es) |
| BR (1) | BR112019023742A2 (es) |
| CA (1) | CA3063965A1 (es) |
| CL (1) | CL2019003557A1 (es) |
| CO (1) | CO2019013718A2 (es) |
| EA (1) | EA201992883A1 (es) |
| IL (1) | IL271067B2 (es) |
| MA (1) | MA49257A (es) |
| MX (1) | MX2019014714A (es) |
| MY (1) | MY202315A (es) |
| PE (1) | PE20200173A1 (es) |
| PH (1) | PH12019502694A1 (es) |
| SG (1) | SG11201911814UA (es) |
| TW (2) | TWI808086B (es) |
| UA (1) | UA127967C2 (es) |
| WO (1) | WO2018224630A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018220169A1 (en) * | 2017-06-02 | 2018-12-06 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| TW202233668A (zh) * | 2020-10-21 | 2022-09-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子 |
| WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| CA2610771A1 (en) | 2005-06-06 | 2006-12-14 | Wyeth | Anti-trkb monoclonal antibodies and uses thereof |
| EA200970469A1 (ru) * | 2006-11-09 | 2010-04-30 | АйАрЭм ЭлЭлСи | Антитела-агонисты рецептора trkb и их применение |
| CN101605556A (zh) * | 2006-12-20 | 2009-12-16 | 瑞纳神经科学公司 | 治疗自体免疫疾病的trkb激动剂 |
| WO2009048605A1 (en) | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| CN101909647A (zh) * | 2007-10-23 | 2010-12-08 | 诺瓦提斯公司 | TrkB抗体用于治疗呼吸病症的用途 |
| US8642035B2 (en) * | 2008-01-17 | 2014-02-04 | Irm Llc | Anti-TrkB antibodies |
| KR101782857B1 (ko) | 2008-02-04 | 2017-09-28 | 레이 라인 지노믹스 에스.피.에이. | 항―ｔｒｋａ 항체 및 이의 유도체 |
| CA2732266A1 (en) | 2008-07-28 | 2010-02-04 | Emory University | Treating various disorders using trkb agonists |
| WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
| WO2011103667A1 (en) * | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
| WO2011156479A2 (en) | 2010-06-09 | 2011-12-15 | Emory University | Trkb agonists and methods of use |
| WO2012027821A1 (en) | 2010-09-03 | 2012-03-08 | The Royal Institution For The Advancement Of Learning / Mcgill University | A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases |
| GB2491106A (en) | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
| EP3143043B1 (en) | 2014-05-16 | 2022-12-14 | Pfizer Inc. | Bispecific antibodies with engineered ch1-cl interfaces |
| EP3328898B8 (en) | 2015-07-28 | 2024-04-10 | 6452728 Canada Corp. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
| WO2017085035A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
| MA51207A (fr) | 2017-11-30 | 2020-10-07 | Regeneron Pharma | Anticorps monoclonaux anti-trkb et leurs procédés d'utilisation |
-
2018
- 2018-06-07 US US16/002,058 patent/US10793634B2/en active Active
- 2018-06-08 BR BR112019023742A patent/BR112019023742A2/pt unknown
- 2018-06-08 PE PE2019002525A patent/PE20200173A1/es unknown
- 2018-06-08 MY MYPI2019007297A patent/MY202315A/en unknown
- 2018-06-08 KR KR1020197037817A patent/KR20200017421A/ko active Search and Examination
- 2018-06-08 MA MA049257A patent/MA49257A/fr unknown
- 2018-06-08 MX MX2019014714A patent/MX2019014714A/es unknown
- 2018-06-08 AR ARP180101558 patent/AR112602A1/es unknown
- 2018-06-08 EP EP18731764.9A patent/EP3635004A1/en active Pending
- 2018-06-08 IL IL271067A patent/IL271067B2/en unknown
- 2018-06-08 TW TW107119755A patent/TWI808086B/zh active
- 2018-06-08 TW TW112123529A patent/TW202342100A/zh unknown
- 2018-06-08 JP JP2019567701A patent/JP7267208B2/ja active Active
- 2018-06-08 WO PCT/EP2018/065107 patent/WO2018224630A1/en active Application Filing
- 2018-06-08 CA CA3063965A patent/CA3063965A1/en active Pending
- 2018-06-08 CN CN201880038098.6A patent/CN110719916B/zh active Active
- 2018-06-08 UA UAA201911908A patent/UA127967C2/uk unknown
- 2018-06-08 SG SG11201911814UA patent/SG11201911814UA/en unknown
- 2018-06-08 EA EA201992883A patent/EA201992883A1/ru unknown
-
2019
- 2019-11-28 PH PH12019502694A patent/PH12019502694A1/en unknown
- 2019-12-05 CL CL2019003557A patent/CL2019003557A1/es unknown
- 2019-12-05 CO CONC2019/0013718A patent/CO2019013718A2/es unknown
-
2020
- 2020-08-26 US US17/002,907 patent/US11866501B2/en active Active
-
2023
- 2023-04-19 JP JP2023068735A patent/JP7505084B2/ja active Active
- 2023-11-28 US US18/520,650 patent/US20240101689A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142041A1 (es) | Anticuerpos anti-il-36r | |
| NZ599438A (en) | Humanized antibodies against human il-22ra | |
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| BR112013032899A2 (pt) | anticorpos anti-axl e utilizações dos mesmos | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| HRP20211935T1 (hr) | Protutijela anti-alfa-sinuklein i njihove uporabe | |
| PE20080036A1 (es) | Anticuerpos humanos para la interleucina-13 (il13) | |
| PE20200173A1 (es) | Anticuerpos anti-trkb | |
| NZ711451A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
| PE20181014A1 (es) | Agentes, usos y metodos para el tratamiento | |
| SA523440043B1 (ar) | أجسام مضادة ضد cd3 إبسيلون جديدة | |
| AR106188A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
| AR122266A1 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| CO2018001010A2 (es) | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por vrsh | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| PH12016501579A1 (en) | Novel anti-presepsin antibody | |
| NZ631473A (en) | Anti-cd52 antibodies | |
| RU2016121542A (ru) | Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения | |
| ZA202205288B (en) | Humanized antibody and method for using the same | |
| PE20220516A1 (es) | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO |